LENZ Therapeutics (LENZ) Cash from Investing Activities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Cash from Investing Activities data on file, last reported at $33.2 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $33.2 million, up 75.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$61.4 million (up 60.03% YoY), and the FY2025 annual result was -$75.7 million, up 51.02% from the prior year.
• Cash from Investing Activities climbed to $33.2 million in Q1 2026 per LENZ's latest filing, from -$89.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $33.2 million in Q1 2026 and troughed at -$170.7 million in Q1 2022.
• A 5-year average of -$27.6 million and a median of -$4.3 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities slumped 47307.22% in 2022, then soared 300100.0% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $13.5 million in 2022, then increased by 12.19% to $15.2 million in 2023, then plunged by 178.18% to -$11.9 million in 2024, then plunged by 657.06% to -$89.8 million in 2025, then surged by 136.92% to $33.2 million in 2026.
• Business Quant data shows LENZ's Cash from Investing Activities at $33.2 million in Q1 2026, -$89.8 million in Q4 2025, and -$4.3 million in Q3 2025.